Precipio (PRPO) vs. Its Rivals Head-To-Head Review

Precipio (NASDAQ:PRPO) is one of 233 public companies in the “Healthcare Providers & Services” industry, but how does it compare to its rivals? We will compare Precipio to similar companies based on the strength of its earnings, institutional ownership, risk, valuation, profitability, analyst recommendations and dividends.

Valuation and Earnings

This table compares Precipio and its rivals revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Precipio	$27.20 million	-$360,000.00	-29.88
Precipio Competitors	$19.16 billion	$301.67 million	7.60

Precipio’s rivals have higher revenue and earnings than Precipio. Precipio is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Precipio and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Precipio	-4.47%	-8.49%	-5.75%
Precipio Competitors	-8.08%	-137.95%	-1.47%

Institutional & Insider Ownership

10.4% of Precipio shares are owned by institutional investors. Comparatively, 56.7% of shares of all “Healthcare Providers & Services” companies are owned by institutional investors. 16.6% of Precipio shares are owned by company insiders. Comparatively, 15.0% of shares of all “Healthcare Providers & Services” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings for Precipio and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precipio	1	0	0	0	1.00
Precipio Competitors	1861	7721	13336	820	2.55

As a group, “Healthcare Providers & Services” companies have a potential upside of 13.51%. Given Precipio’s rivals stronger consensus rating and higher probable upside, analysts plainly believe Precipio has less favorable growth aspects than its rivals.

Risk and Volatility

Precipio has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500. Comparatively, Precipio’s rivals have a beta of 0.98, indicating that their average stock price is 2% less volatile than the S&P 500.

Summary

Precipio rivals beat Precipio on 9 of the 13 factors compared.

Precipio Company Profile

Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. The company is based in New Haven, Connecticut.